Skip to main content

Consensus Against Interventional Injections for Chronic Spinal Pain BMJ has published a clinical practice guideline re

Social Author Name
Dr. John Cush
Tweet Content
Consensus Against Interventional Injections for Chronic Spinal Pain BMJ has published a clinical practice guideline resulting from the work of an international, multidisciplinary panel addressing chronic spine pain (≥3 months duration) not associated with cancer or https://t.co/mCsz88JACh

Topline results from Phase 3b APEX study, comparing guselkumab to placebo in biologic naive #PsA pts - showed significan

Social Author Name
Dr. John Cush
Tweet Content
Topline results from Phase 3b APEX study, comparing guselkumab to placebo in biologic naive #PsA pts - showed significant improvement by ACR20 and significantly less Xray progression of structural damage (vs PB) at Week 24 https://t.co/0Ra8eUeBOi https://t.co/0dwOSxjVxs

Matched cohort study of 83,811 #RA pts showed RA had a 12% increased risk of avoidable hospitalizations (CHF, pulmonary

Social Author Name
Dr. John Cush
Tweet Content
Matched cohort study of 83,811 #RA pts showed RA had a 12% increased risk of avoidable hospitalizations (CHF, pulmonary edema; (IRR 1.12). Predictors of ACSC hosp. were age, Steroids, ambulatory comorbid Dxs. ambulatory care access & ^ primary care may reduce this risk. https://t.co/AxQVoXoxxx

Topline results from Phase 3b APEX study, comparing guselkumab to placebo in biologic naive #PsA pts - showed significan

Social Author Name
Dr. John Cush
Tweet Content
Topline results from Phase 3b APEX study, comparing guselkumab to placebo in biologic naive #PsA pts - showed significant improvement by ACR20 and significantly less Xray progression of structural damage (vs PB) at Week 24 https://t.co/7sY1sX9B3O https://t.co/EislRI5WAy

FDA announced approval of Inebilizumab (Uplizna; Amgen), 1st approved Rx for IgG4-related disease (targets CD19+ B cells

Social Author Name
Dr. John Cush
Tweet Content
FDA announced approval of Inebilizumab (Uplizna; Amgen), 1st approved Rx for IgG4-related disease (targets CD19+ B cells). IG4-related Dz is estimated to affect 20,000 in the USA. List price is $140,248.50 per dose, After two initial loading doses it is given q 6 mos. https://t.co/zHD2Yv3PjI

2nd Opinions in Rheumatology

Join The Discussion

#RheumTwitter—Heading to the highly anticipated State-of-the-Art Clinical Symposium (SOTA), April 4-6, in Chicago? Sha

Social Author Name
American College of Rheumatology
Tweet Content
#RheumTwitter—Heading to the highly anticipated State-of-the-Art Clinical Symposium (SOTA), April 4-6, in Chicago? Share your meeting experience on social & be sure to include #SOTA25 in your posts. We can’t wait to see you there! https://t.co/HZTZUm2UfG

📢 Federal funding for lupus research and the Lupus Research Program within the Department of Defense hang in the bala

Social Author Name
Lupus Research
Tweet Content
📢 Federal funding for lupus research and the Lupus Research Program within the Department of Defense hang in the balance as Congress debates spending priorities. 🔬 Investing in lupus research – and all medical research – is one of the wisest investments we can make. That’s why https://t.co/OgWo5z0fMB

🎉 Today's Annual Scientific Conference kicked off with The CARRA Registry Retreat! The retreat brought together physi

Social Author Name
CARRA
Tweet Content
🎉 Today's Annual Scientific Conference kicked off with The CARRA Registry Retreat! The retreat brought together physician-PIs, research coordinators, research managers and patients/caregivers involved with the CARRA Registry. 💙 #CARRA2025 #pedsrheum https://t.co/GYYHAjsIdK
Subscribe to
×